Patent settlements in which brand-name drugmakers strike a deal to keep generic competition off the market provide consumers with generic options sooner than would be the case if lawsuits were fought to the end, Actavis lawyers argued in a brief to the Supreme Court. The Federal Trade Commission is suing Actavis for antitrust law violations in a patent settlement case. The FTC and the Congressional Budget Office have found that such "pay-for-delay" deals cost taxpayers billions of dollars.

Full Story:

Related Summaries